Home >> Tag Archives: Illumina

Tag Archives: Illumina

Illumina, Pillar Biosciences announce partnership

September 2023—Illumina and Pillar Biosciences announced a strategic partnership to make Pillar’s suite of oncology assays commercially available worldwide as part of Illumina’s portfolio of oncology products. The companies say the agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques.

Read More »

Illumina launches DRAGEN 4.2

August 2023—Illumina launched the latest version of its DRAGEN software, version 4.2, for analyzing next-generation sequencing data. New features of the software include increased single nucleotide variant and structural variation calling accuracy powered by an enhanced machine learning model and multigenome graph, improvements in small copy number variation calling accuracy with joint SV/CNV calling, and the addition of four targeted callers for carrier screening—HBA 1/2, CYP21A2, RHD/RHCE, and LPA.

Read More »

Illumina launches Connected Insights software

May 2023—Illumina announced the release of Connected Insights, a cloud-based software for tertiary analysis of clinical next-generation sequencing data. The software enables labs to connect to a network of more than 45 third-party knowledge sources that provide digital directories for precision oncology, illustrating connections between cancer variants and therapies, citing evidence, and aiding analysis of complex cancer genomic profiles. It can also link users to regional guidelines, clinical trial databases, drug labels, and a private collection of data from previous cases within a customer’s laboratory. As the use of clinical NGS testing grows, Illumina says it will expand the software’s capabilities across other disease areas.  

Read More »

Illumina introduces pan-cancer CDx

July 2022—Illumina announced that a companion diagnostic indication has been added to its CE-marked in vitro diagnostic TruSight Oncology Comprehensive (EU) test. The CDx pan-cancer indication will allow identification of cancer patients with solid tumors who are positive for neurotrophic tyrosine receptor kinase gene fusions including NTRK1, NTRK2, or NTRK3 and who may benefit from targeted therapy with Bayer’s Vitrakvi (larotrectinib), a genomically matched treatment.

Read More »

ArcherDX, Illumina comarketing partnership

February 2020—ArcherDX announced a nonexclusive, multiyear partnership with Illumina intended to broaden access of next-generation-sequencing­–based oncology testing, including companion diagnostics for therapeutic selection, personalized monitoring, and recurrence surveillance IVD tests, upon FDA approval.  

Read More »

Illumina to buy PacBio for $1.2 billion

Nov. 7, 2018—Illumina announced it will acquire Pacific Biosciences for approximately $1.2 billion. With this acquisition, Illumina will be positioned to provide integrated workflows and novel innovations that bring together both Illumina’s short-read sequencing platforms with PacBio’s long-read sequencing capabilities to help researchers advance their discoveries faster and clinicians offer new tests economically. “PacBio’s unmatched accuracy mirrors that of Illumina’s ...

Read More »

Illumina launches TruSight Oncology 500

Nov. 1, 2018—Illumina  launched its TruSight Oncology 500, a comprehensive next-generation sequencing assay. TSO 500 uses DNA and RNA to identify multiple variant types, including small nucleotide variants, indels, splice variants, fusions, and tumor mutational burden and microsatellite instability from the same formalin-fixed, paraffin-embedded tumor sample. The panel contains 1.94 Mb of genomic content to measure TMB and offers sophisticated variant ...

Read More »

NextSeq 550Dx NGS system, 2/18

February 2018—Illumina introduced its NextSeq 550Dx instrument, the company’s second FDA-regulated and CE-IVD-marked next-generation-sequencing system. Illumina also announced that the intended use for the MiSeqDx instrument now includes the use of DNA libraries generated from formalin-fixed, paraffin-embedded tissues.

Read More »

Whole genome sequencing library prep kit, 12/17

December 2017—Illumina announced the availability of a whole genome sequencing library prep product, Nextera DNA Flex. The kit enables direct input of blood and saliva samples, eliminating the need for ancillary equipment and reagents to extract DNA and quantify sample concentration prior to sequencing. It also removes steps in the library prep workflow, such as mechanical fragmentation of DNA, quantification, and normalization.

Read More »

Bio-Rad, Illumina partnership, 3/16

March 2016—Bio-Rad Laboratories and Illumina announced an exclusive partnership to develop a comprehensive next-generation sequencing workflow for single-cell analysis. The end-to-end commercial solution will enable high-throughput sequencing of thousands of individual cells.

Read More »

Novogene, Illumina to co-develop NGS system, 2/16

February 2016—Novogene and Illumina have entered into an agreement to jointly develop advanced clinical applications in the fields of reproductive health and oncology based on next-generation sequencing technology. The companies will work together to develop a user-friendly diagnostic system for clinical prenatal DNA and oncology testing in the Chinese market.

Read More »

Extended genomics portfolio, 2/16

February 2016—Illumina launched its MiniSeq Sequencing System and, during a presentation at the J.P. Morgan Healthcare Conference, Jan. 11­–14 in San Francisco, introduced the Infinium XT and previewed Project Firefly, which will lead to the commercialization of a new semiconductor-based sequencing system.

Read More »

Newsbytes, 12/15

December 2015—Fellowship blends clinical informatics and pathology: Ask Rebecca Johnson, MD, and her colleague Bruce Levy, MD, about a newly approved fellowship program that allows fellows to train concurrently in clinical informatics and any other of the pathology subspecialties, and they’ll give you a similar answer: This has been in the works for a long time.

Read More »

NGS cancer panel, 11/15

November 2015—Illumina has launched TruSight Tumor 15, a next-generation sequencing panel designed to identify sequence variants in 15 genes commonly associated with marketed therapeutics. The sequencing panel is optimized for damaged and degraded formalin-fixed, paraffin-embedded tumor samples, enabling low frequency somatic variant detection from limited nucleic acid inputs.

Read More »

Newsbytes, 9/15

September 2015—How site visits led to an LIS selection at Stanford: Seven gets all the attention, but five turned out to be the lucky number for a Stanford University Medical Center team charged with selecting a new laboratory information system. Visiting five installation sites in five cities in five days was “probably the most important aspect of the whole process,” says Brent Tan, MD, PhD, director of clinical laboratory informatics at Stanford.

Read More »

Four new systems from Illumina, 4/15

April 2015—Illumina has launched the HiSeq X Five System and HiSeq 3000/4000 systems and has introduced the NextSeq 550 System, an NGS system enabled for array scanning. The HiSeq X Five System is designed for laboratories wanting to take advantage of HiSeq X technology for human whole genome sequencing at a smaller scale. At full utilization, the system, which consists of five individual HiSeq X instruments, provides the throughput to sequence more than 9,000 genomes a year.

Read More »

NGS solution for forensic genomics, 3/15

March 2015—Illumina launched the MiSeq FGx Forensic Genomics System, a fully validated forensic next-generation sequencing system that simultaneously interrogates short tandem repeats and other valuable genetic markers, including single nucleotide polymorphisms, to provide informative DNA profiles. The system enables robust analysis of a range of genetic markers in a single workflow.

Read More »

FDA clears test for CHD events, 3/15

March 2014—The Food and Drug Administration cleared a screening test that predicts a patient’s risk of future coronary heart disease events, such as heart attacks. The test is cleared for use in all adults with no history of heart disease, but studies submitted by the company and reviewed by the FDA show that the test is better at discerning this risk in women, particularly black women.

Read More »

Reagent kits, 12/14

December 2014—Illumina announced new reagent kits for the HiSeq X Ten and HiSeq 2500 sequencing systems. For HiSeq X Ten Systems, the HiSeq X HD v2 Reagent Kit adds flexibility to population-scale human whole-genome sequencing by supporting an expanded menu of library preparation options.

Read More »

Undiagnosed disease test, 12/13

December 2013—Illumina announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory. This new service uses whole genome sequencing to assist physicians in identifying the underlying genetic cause of a rare or undiagnosed disease.

Read More »

Illumina launches TruSight One sequencing panel, 11/13

Illumina launched its TruSight One sequencing panel, which targets 4,813 genes with known associated clinical phenotypes. Clinical research laboratories can use this panel to expand existing menus, streamline workflows, or create an entire portfolio of sequencing options, with benefits including increased productivity, reduced handling errors, and decreased costs.

Read More »

NGS-based tumor profiling solution, 5/1:84

Illumina’s TruSight Tumor, for NGS-based somatic variant detection in solid tumors, provides optimized amplicon-based library preparation of 26 oncogenes and tumor suppressor genes selected for their involvement in common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.

Read More »
CAP TODAY
X